SK's epilepsy drug

Researchers of SK Biopharmaceuticals conduct research at a company lab in Daejeon, Monday. The pharmaceutical unit of SK Holdings said that it reached an agreement with the U.S. Food & Drug Administration (FDA) under which SK Biopharmaceuticals will receive U.S. approval for its new epilepsy drug if the medicine passes FDA’s safety test only, while being exempted from its strenuous remedial-effect test. / Courtesy of SK Holdings